|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:N05AH03
|
|
gptkbp:bioavailability
|
60-80%
|
|
gptkbp:CASNumber
|
gptkb:132539-06-1
|
|
gptkbp:color
|
yellow crystalline powder
|
|
gptkbp:halfLife
|
21-54 hours
|
|
gptkbp:hasBindingDBID
|
BID:500001
|
|
gptkbp:hasInChIKey
|
IKHBVPDZYYGQTP-UHFFFAOYSA-N
|
|
gptkbp:hasLogP
|
2.7
|
|
gptkbp:hasMolecularFormula
|
gptkb:C17H20N4S
|
|
gptkbp:hasPatent
|
US4681893A
|
|
gptkbp:hasPDBLigandID
|
OZA
|
|
gptkbp:hasPharmGKBID
|
PA450464
|
|
gptkbp:hasSMILES
|
CN1CCN(C2=Nc3cc(Sc4ccccc4)ccc3C2=C1)C
|
|
gptkbp:hasUNII
|
7M546I6E82
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL1539
|
|
gptkbp:indication
|
bipolar disorder
schizophrenia
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
antipsychotic medication
|
|
gptkbp:meltingPoint
|
195-197°C
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP2C9
gptkb:CYP2D6
|
|
gptkbp:molecularWeight
|
312.44
|
|
gptkbp:name
|
Olanzapine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
4585
4425
CHEBI:7737
D08364
DB00334
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
weight gain
extrapyramidal symptoms
dyslipidemia
somnolence
hyperglycemia
|
|
gptkbp:solubility
|
practically insoluble in water
|
|
gptkbp:synonym
|
gptkb:Zyprexa
LY170053
|
|
gptkbp:target
|
gptkb:Histamine_H1_receptor
Alpha-1 adrenergic receptor
Dopamine D2 receptor
Muscarinic acetylcholine receptor M1
Serotonin 5-HT2A receptor
|
|
gptkbp:bfsParent
|
gptkb:lidocaine
|
|
gptkbp:bfsLayer
|
6
|